Home/Hansa Biopharma/Renée Aguiar-Lucander

RA

Renée Aguiar-Lucander

Chief Executive Officer

Hansa Biopharma

Therapeutic Areas

Autoimmune Diseases Transplantation Gene Therapy

Hansa Biopharma Pipeline

Drug	Indication	Phase
Imlifidase	Desensitization in Kidney Transplantation	Approved (EU)
HNSA-5487	Next-Generation IgG-cleaving Enzyme	Preclinical/Clinical

Leadership Team at Hansa Biopharma

Chief Scientific & Technology Officer

Evan Ballantyne

Chief Financial Officer

Maria Törnsén

Chief Operating Officer and President U.S.

View full Hansa Biopharma profile